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ABSTRACT 
Background: Despite the high prevalence of depression in the United States, 
few studies have identified which adverse effects (AEs) patients are willing or 
unwilling to tolerate when receiving antidepressants. 
Objective: The aim of this study was to identify reasons for discontinuation 
and noncompliance with antidepressant medications, the impact of AEs on 
compliance and quality of life (assessed using impact of AEs on activities of 
daily living), and patients' suggestions for improving their medication, using a 
patient survey. 
Methods: Patients aged 18 to 65 years with mild to severe depression were 
randomly selected by their physicians to be sent an invitation to complete the 
42-question survey. Three hundred physicians nationwide assessed the severity 
of depression and symptoms of anxiety in each respondent, using their judgment. 
Patients were asked specific questions to assess reasons for discontinuation/ 
noncompliance. Patients were also asked to rate AEs based on how difficult they 
were to "live with," and what 2 aspects of their antidepressant medication they 
would change if they could. 
Results: In a separate, concurrent study, physicians classified 175 (50%) as 
mildly to moderately depressed and 84 (24%) as severely depressed. Ninety-one 
respondents (26%) were classified as having symptoms of anxiety. Two hundred 
seven patients (60%) indicated they had discontinued treatment with an anti- 
depressant agent at some point in their lives, the most common reason for which 
was lack of efficacy (92 patients [44%]). Of the 344 patients currently being treat- 
ed with an antidepressant, 75(22%) reported noncompliance. The most common 
reasons for noncompliance were "have trouble remembering to take it" (19/44 
patients [43%]), "gained a lot of weight" (11/41 [27%]), "unable to have an orgasm" 
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(8/40 [20%]), and "lost interest in sex" (8/41 [20%]). The 4 AEs patients ex- 
pressed as "extremely difficult to live with" were "weight gain" (104 patients 
[31%]), "unable to have erection" (83 [25%]), "difficulty reaching orgasm" 
(80 [24%]), and "tired during the day/no energy" (69 patients [21%]). The 3 most 
frequently cited improvements patients (n -- 327) would make to their medica- 
tions were better efficacy (176 patients [54%]) and eliminating AEs related to 
sexual desire and weight gain (112 [34%] and 105 [32%] patients, respectively). 
Conclusions: The findings of this survey of patients with mild to severe 
depression suggest hat compliance, and hence efficacy, can be promoted by 
(1) understanding what patients expect and desire from the antidepressants 
they are prescribed and (2) prescribing antidepressants a sociated with low 
rates of weight gain, sexual dysfunction, or tiredness. (Curr Ther Res Clin Exp. 
2005;66:96-106) Copyright © 2005 Excerpta Medica, Inc. 
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INTRODUCTION 
Depression is a common medical disorder, with one comorbidity report re- 
vealing a 10.3% 1-year risk and a 17.1% lifetime risk for major depression 
in people in the United States. 1Despite that the total cost of depression is 
$44 billion per year and that suicide is the eighth leading cause of death in 
the United States, few studies have assessed compliance with antidepressant 
medications in patients with depression. 2,3 Only 1% to 2% of publications con- 
cerning the treatment of affective disorders have explored factors associat- 
ed with medication discontinuation. 4 One study of reports concerning com- 
pliance with antidepressants for the years 1975 to 1996 showed that patients 
used only 65% of their recommended treatment. 5 In a study of antidepressant 
therapy in the primary care setting, 53% of patients discontinued their anti- 
depressant treatment after they experienced clinical improvement, and of patients 
who discontinued treatment for any reason, 24% did not inform their physicians. 6 
A patient's reasons for noncompliance may be multifactorial and include mis- 
perceptions about the illness, concern about adverse ffects (AEs), lack of effi- 
cacy, cost, and cultural issues. 7,8 A physician's ability and desire to address a 
patient's concerns and attitudes about antidepressants might enhance compli- 
ance and improve outcome. 9 Patient education and the management of AEs have 
also been found to be helpful. 1° A physician's initial choice of antidepressant 
medication can impact compliance, suggesting that this decision by physicians 
might play a vital role in a patient's willingness to take his or her antidepressant 
medication as prescribed. 11Improved tolerability would be expected to lead to 
greater compliance and result in a more favorable treatment outcome. 
Compared with the long-prescribed tricyclic antidepressants and mono- 
amine oxidase inhibitors, newly developed medications offer comparable efficacy, 
fewer associated AEs, and a markedly reduced risk for serious AEs (eg, changes 
in blood pressure, severe adverse drug interactions). 7 
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Based on a MEDLINE search (key terms: patient compliance, patient satisfaction, 
adherence, antidepressant, depression, and depressive disorder; years: 1966-2005), 
patient input is rarely sought when studying drug discontinuation. Bull et a112 
assessed why patients recently prescribed fluoxetine or paroxetine discontinued 
their medication and found that 43% of patients who discontinued treatment did 
so because of fatigue or drowsiness. However, the literature search revealed no 
studies of what aspects of their antidepressant patients would change if they 
could design their own. 
The aim of this study was to identify reasons for discontinuation a d noncom- 
pliance with antidepressant medications, the impact of AEs on compliance and 
quality of life (assessed using impact of AEs on activities of daily living [ADLs]), 
and patients' suggestions for improving their medication, using a patient survey. 
MATERIALS AND METHODS 
Study Investigators 
The 42-question survey was administered by Market Measures Interactive 
(MMI), LP, Princeton, New Jersey, a marketing firm contracted by the study spon- 
sor. A group of 300 physicians (103 general/family practitioners, 100 psychia- 
trists, and 97 internists) was recruited to participate in the study. MMI selected 
this group from its Medical Marketing Conference Panel, based on the physicians' 
antidepressant-prescribing practices, as follows: for psychiatrists, antidepres- 
sants typically prescribed to >75 patients per month; for internists and primary 
care physicians, antidepressants typically prescribed to >25 patients per month. 
Survey Participants 
Each physician on the panel was asked to select, from among their patients 
prescribed treatment for depression, 6 patients to complete the survey (2 patients 
each with mild to moderate depression, severe depression, and predominant 
depression with symptoms of anxiety). Patients were selected if they were aged 
18 to 65 years, had mild to severe depression based on the physician's judg- 
ment, and had recently been prescribed an antidepressant medication. From 
this pool of 1011 patients, 750 were randomly selected, using a computer- 
generated list of random numbers, to receive a card inviting them to complete 
the survey and a letter explaining the details of the study. To achieve a balanced 
geographic representation, randomization was stratified by US region (Northeast, 
South, Midwest, and West). 
The survey was considered by the sponsor exempt from the institutional 
review process, as specified in the US Food and Drug Administration's Code of 
Federal Regulations. 13 Participation i  the survey was voluntary. Surveys were 
mailed only to patients who returned the invitation card. Compensation was 
provided to participating physicians and patients. To ensure confidentiality, 
patients were instructed not to include their names when completing and re- 
turning the survey. 
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Survey Components 
Patients were asked to provide their age, sex, race/ethnicity, marital status, 
and household income. Patients were also instructed to self-assess the sever i ty 
of their depress ion (mild, moderate,  or severe).  
Questions to Assess Reasons 
for Discontinuation~Noncompliance 
To ident i fy reasons  for ant idepressant  d iscont inuat ion,  pat ients  were  
asked: 
• Has a doctor  ever prescr ibed a depress ion medicine for you that you 
complete ly  s topped taking for one reason or another? 
• If yes: How many medicines did you try that you complete ly  s topped 
taking for one reason or another? 
• Why did you complete ly  stop taking your  medicine? 
Following the third question, a checklist of 20 reasons was provided (eg, "lack 
of efficacy, .... side effects," "cost/ lack of insurance," resolution of symptoms,"  
"did not need it anymore").  
To identify reasons for noncompl iance with pat ients'  current ant idepressant  
regimens, pat ients were asked: 
• Do you always take your  current ant idepressant  exactly as the doctor  
has recommended?  
• If no, how often does each of the following reasons make you NOT take 
your ant idepressant exactly as your physician has recommended? 
The second question was followed by a list of 19 reasons for noncompliance ( g, 
specific AEs, cost, safety), with instructions to indicate the frequency with which 
each reason applied, using a 5-point Likert scale (1 -- "is never a reason" to 5 = 
"is often a reason"). 
Questions to Identify Adverse Effects and 
Their Impact on Quality of Life 
To assess  the impact  of AEs on pat ients '  ADLs, the survey  prov ided a list of 
11 AEs, with the opt ion to write in others.  For each AE, pat ients  were asked: 
• Have you ever exper ienced this side effect as a result of the current anti- 
depressant  you take most  often? 
• If you have exper ienced this side effect, how difficult was the side effect 
to live with? 
• If you have exper ienced this side effect as a result of your  current 
depress ion medication, do you exper ience the side effect all of the time, 
somet imes,  or did you exper ience it when you started the medication, 
but then it went away? 
The second quest ion was fol lowed by a 5-point Likert scale (1 = "not at all 
difficult," 2 = "not very  difficult," 3 = "somewhat  difficult," 4 = "very difficult," 
or 5 = "extremely  difficult"). 
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Questions to Assess Patients" Opinions 
Concerning Improving Medication 
To assess patients' views on improving their antidepressant medications, the 
survey provided a list of 7 potential improvements (eg, fewer specific AEs, "less 
expensive," "complete remission of depressive symptoms"), with the option to 
write in others, and asked: 
• If depression medication could be improved, in just 2 ways, which of the 
following would you choose? 
Data Analysis 
Data were tallied and frequency counts were completed by MMI. Formal sta- 
tistical analysis of the data was not performed. 
RESULTS 
Study Population 
A total of 750 patients were selected to receive an invitation card. Of 664 sur- 
veys mailed to patients, 350 were returned (53% response rate). Two hundred 
twelve respondents (61%) were treated by psychiatrists, 110 (31%) by general/ 
family practitioners, and 28 (8%) by internists. One hundred eighty-two patients 
(52%) reported they were prescribed ___2 concurrent antidepressants at some 
time in their lives. Of the 350 respondents, 260 (74%) identified a specific anti- 
depressant they had taken most recently or were currently prescribed. Patients 
who identified medications by name (n = 260) cited fluoxetine (84 patients [32%]), 
sertraline (52 [20%]), paroxetine (40 [15%]), bupropion sustained release (34 
[13%]), citalopram (29 [11%]), and venlafaxine xtended release (21 [8%]). In 
self-assessing their depression (n -- 347), 241 patients (69%) categorized it as 
mild/moderate, and 106 (31%) defined it as severe. However, in a separate, con- 
current study, physicians categorized 175 patients (50%) as mildly to moderately 
depressed, 84 (24%) as severely depressed, and 91 (26%) as having symptoms 
of anxiety. 
Survey Components 
Reasons for Discontinuation~Noncompliance 
Two hundred seven respondents (60%) indicated they had completely dis- 
continued at least 1 antidepressant medication at some point in their lives. 
The most frequently cited reason for discontinuation was lack of efficacy 
(92 patients [44%]). AEs accounted for the second most common reason for 
discontinuation (  = 204), with the most common AE being "didn't like the way 
the medicine made me feel" (75 patients [37%]), followed by "lost interest in sex" 
(46 [23%]), "tiredness" (36 [18%]), and "weight gain" (32 [16%]). 
Of the 350 patients who returned the survey, 341 (97%) had been given at 
least 1 current prescription for an antidepressant medication. Of this subgroup, 
75 (22%) indicated they had been noncompliant with their currently prescribed 
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antidepressant regimen. The 10 most common reasons for noncompliance indi- 
cated by patients are shown in Figure 1 and included "have trouble remember- 
ing to take it" (19/44 patients [43%]), "gained a lot of weight" (11/41 [27%]), 
"couldn't have an orgasm" (8/40 [20%]), and "lost interest in sex" (8/41 [20%]). 
Adverse Effects and Their Impact 
on Compliance and Quality of Life 
The frequencies with which patients reported experiencing specific AEs are 
shown in Figure 2. Patients who responded to this question most frequently 
cited "tired during the day/no energy" (153/310 [49%]), "dry mouth" (151/313 
[48%]), and "lost interest in sex" (142/304 [47%]). 
The AEs most frequently rated as "extremely difficult to live with" are shown 
in Figure 3. Patients most frequently cited "weight gain" (38/124 patients [31%], 
"unable to have erection" (6/24 [25%]), "difficulty reaching orgasm" (29/122 
[24%]), and "tired during the day/no energy" (31/145 [21%]). 
In response to the question concerning whether AEs were experienced all of 
the time or sometimes or resolved, "weight gain" was assessed from the data 
as being the most common AE (70/118 [59%]), followed by "lost interest in sex" 
(60/134 [45%]), and "difficulty reaching orgasm" (55/128 [43%]). 
Improving Medication 
Among patients who indicated which aspects of their medications they would 
improve (n = 327), efficacy was cited most frequently (176 patients [54%]), fol- 
lowed by eliminating AEs related to sexual desire and weight gain (112 [34%] and 
105 [32%] patients, respectively). 
Have trouble remembering to take it 
Gained a lot of weight 
Couldn't have an orgasm 
Lost interest in sex - 
Takes less when feels better - 
Wants to take less medication -
Gave patient headaches 
Too expensive 
Worried about safety of medication 
Too frequent administration 
0 ll0 210 310 410 510 
% of Patients 
Figure 1. The 10 most  common reasons fo r  noncompl iance  repor ted  by pat ients  who 
received a prescr ip t ion  fo r  at  least 1 ant idepressant  med icat ion .  
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Tired during the day/no energy 
Dry mouth 
Lost interest in sex 







Unable to have erection 
o (o 2~0 3'0 4~0 ~ - - I  50 60 
% of Patients 
Frequency of adverse effects reported by patients who  had received a 
prescr ipt ion for at least 1 ant idepressant medicat ion.  
Weight gain 
Unable to have erection 
Difficulty reaching orgasm 
Tired during the day/no energy 









[ ]  
o ~ ~'o ~ ~'o ~'~ ~o 35 
% of Patients 
Frequency of adverse effects (AEs) reported by patients as "extremely diffi- 
cult to live with."  
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DISCUSSION 
Although individual patient opinions vary, these survey results provide a start- 
ing point for understanding the impact of AEs on patients' lives. Sixty percent 
of the respondents indicated ahistory of treatment discontinuation. I  addition 
to "lack of efficacy," "lost interest in sex," "tired during the day/no energy," and 
"gained a lot of weight" were among the most common AEs that led to discon- 
tinuation. These AEs occur more often with certain classes of antidepressants, 
including, but not limited to, selective serotonin reuptake inhibitors. In addition 
to patients indicating discontinuation, an additional 22% of patients indicated 
noncompliance, with the chief reasons being "trouble remembering to take it," 
"gained a lot of weight," and sexual AEs. Finally, "weight gain" and sexual AEs 
were the ALEs most difficult o "live with" according to patients. 
These results suggest hat there are ways for physicians to better serve 
patients and to potentially enhance treatment response and quality of life. 
Specifically, limiting the AEs that patients most want to avoid may increase 
patient satisfaction and promote compliance. The primary problems that patients 
described in this study can be classified into 2 categories--pharmacologic/ 
pharmacokinetic properties and adverse effects (tolerability). Difficulty with 
pharmacologic/pharmacokinetic properties, such as lack of response to treat- 
ment, can be addressed through research and development of more effective 
antidepressants. Until then, prescribing medications that can be dosed once or 
twice daily would reduce the number of doses patients must remember to take, 
thereby enhancing compliance. 14All antidepressants that have become avail- 
able in the United States in the past 15 years meet his goal. So why, then, would 
patients till not derive the desired response to treatment? We believe most of 
these individuals are not dosed adequately or discontinue treatment as a con- 
sequence of intolerable AEs. It is not entirely clear which AEs patients find least 
acceptable. Interestingly, some of the most common AEs (ie, dry mouth, insom- 
nia, nausea/diarrhea, and headache) were not the ones patients found most dif- 
ficult to "live with." Our survey found that the 3 AEs patients most wanted to 
avoid were weight gain, sexual AEs, and tiredness. Typically, these AEs also 
were experienced much, if not all, of the time and did not decrease with time. 
These findings are consistent with those from prior studies. 15-17 
The results of our survey might assist physicians in selecting antidepres- 
sants for patients by providing data regarding which AEs might be most dif- 
ficult for patients to accept. Patients might prefer medications that have a 
reduced risk for weight gain, sexual AEs, and tiredness. Avoiding these AEs 
might promote compliance and thus enhance fficacy in patients who other- 
wise may prematurely discontinue treatment. Patients who continue treat- 
ment have an increased likelihood of response. 18This, at least in part, address- 
es the most common reason patients topped taking their medication--the 
sense that they were not feeling any better. 
Proper patient education might promote compliance. Unfortunately, edu- 
cation might not convince patients to take their medication, especially if
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the AEs associated with it significantly compromise their quality of life. 
Although patient education is seemingly an obvious solution, it has not 
yet shown consistent results in improving compliance. Specifically, in a 
prospective study of compliance, Mundt et al J9 determined that approxi- 
mately half of patients discontinued their antidepressant medication by 
week 12. This rate was not statistically significantly improved with patient 
education and is consistent with our retrospective survey data, which indi- 
cated that 60% of patients had discontinued their antidepressant use at some 
point. 
Limitations of this study include lack of a placebo control, moderate sam- 
ple size, and possible selection bias in the 53% of patients who returned 
their surveys. It is possible that patients with more severe illness are more 
willing to accept AEs, at least temporarily. Other limitations include un- 
known dosing regimens and names of antidepressants prescribed. Pa- 
tients might have altered their dosing based on AEs and had a good out- 
come as a result. 2° This study was not designed to capture this group of 
patients. Inappropriate antidepressant dose or class would likely contribute 
to the types of AEs experienced, and impact efficacy. Nonetheless, the data 
presented provide initial insight into an area largely based on secondhand 
information obtained through individual patient reports to individual pre- 
scribers. A retrospective survey approach to determining compliance has 
also been reported by Bultman and Svarstad. 21 In their telephone survey, 
82% of patients reported missing or discontinuing antidepressant dosing. 
These data corroborate our finding that lack of compliance is not a small 
problem. 
Based on these findings, future studies to confirm this hypothesis might 
provide physicians with suggestions for making treatments more acceptable 
to patients. Additional research to develop better-tolerated antidepressants 
also is needed. 
CONCLUSIONS 
The findings of this survey of patients with mild to severe depression sug- 
gest that compliance, and hence efficacy, can be promoted by (1) under- 
standing what patients expect and desire from the antidepressants they are 
prescribed and (2) prescribing antidepressants a sociated with low rates of 
weight gain, sexual dysfunction, or tiredness. 
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